IDH3A and glioblastoma: Another challenge in evaluating more historical literature is the recent change by the World Health Organization (WHO) to a primarily molecular-based classification schema for GBM; per the current fifth edition, GBM is now, by definition, isocitrate dehydrogenase (IDH) wild-type, but GBM was previously inclusive of any IDH status.